234 related articles for article (PubMed ID: 24684162)
1. Partial clinical response to anakinra in severe palmoplantar pustular psoriasis.
Tauber M; Viguier M; Alimova E; Petit A; Lioté F; Smahi A; Bachelez H
Br J Dermatol; 2014 Sep; 171(3):646-9. PubMed ID: 24684162
[TBL] [Abstract][Full Text] [Related]
2. Treatment of pustular psoriasis with anakinra: a statistical analysis plan for stage 1 of an adaptive two-staged randomised placebo-controlled trial.
Cro S; Smith C; Wilson R; Cornelius V
Trials; 2018 Oct; 19(1):534. PubMed ID: 30285894
[TBL] [Abstract][Full Text] [Related]
3. Successful response in a case of severe pustular psoriasis after interleukin-1β inhibition.
Skendros P; Papagoras C; Lefaki I; Giatromanolaki A; Kotsianidis I; Speletas M; Bocly V; Theodorou I; Dalla V; Ritis K
Br J Dermatol; 2017 Jan; 176(1):212-215. PubMed ID: 27105586
[TBL] [Abstract][Full Text] [Related]
4. Successful therapy with anakinra in a patient with generalized pustular psoriasis carrying IL36RN mutations.
Hüffmeier U; Wätzold M; Mohr J; Schön MP; Mössner R
Br J Dermatol; 2014 Jan; 170(1):202-4. PubMed ID: 23909475
[No Abstract] [Full Text] [Related]
5. Treatment of palmoplantar psoriasis with infliximab: a randomized, double-blind placebo-controlled study.
Bissonnette R; Poulin Y; Guenther L; Lynde CW; Bolduc C; Nigen S
J Eur Acad Dermatol Venereol; 2011 Dec; 25(12):1402-8. PubMed ID: 21349113
[TBL] [Abstract][Full Text] [Related]
6. A small population, randomised, placebo-controlled trial to determine the efficacy of anakinra in the treatment of pustular psoriasis: study protocol for the APRICOT trial.
Cornelius V; Wilson R; Cro S; Barker J; Burden D; Griffiths CEM; Lachmann H; McAteer H; Reynolds N; Pink A; Warren RB; Capon F; Smith C
Trials; 2018 Aug; 19(1):465. PubMed ID: 30157880
[TBL] [Abstract][Full Text] [Related]
7. A randomised placebo controlled trial of anakinra for treating pustular psoriasis: statistical analysis plan for stage two of the APRICOT trial.
Cro S; Patel P; Barker J; Burden DA; Griffiths CEM; Lachmann HJ; Reynolds NJ; Warren RB; Capon F; Smith C; Cornelius V
Trials; 2020 Feb; 21(1):158. PubMed ID: 32041649
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of ustekinumab in refractory palmoplantar pustular psoriasis.
Morales-Múnera C; Vilarrasa E; Puig L
Br J Dermatol; 2013 Apr; 168(4):820-4. PubMed ID: 23210683
[TBL] [Abstract][Full Text] [Related]
9. Biologic therapy in erythrodermic and pustular psoriasis.
Levin EC; Debbaneh M; Koo J; Liao W
J Drugs Dermatol; 2014 Mar; 13(3):342-54. PubMed ID: 24595581
[TBL] [Abstract][Full Text] [Related]
10. Palmoplantar pustular psoriasis following initiation of a beta-blocker: disease control with low-dose methotrexate.
Stanford CW; Kollipara R; Melookaran AM; Hall JC
Cutis; 2014 Sep; 94(3):153-5. PubMed ID: 25279477
[TBL] [Abstract][Full Text] [Related]
11. Palmoplantar pustular psoriasis: successful therapy with efalizumab after non-response to infliximab.
Wozel G; Vitéz L; Meurer M
Acta Dermatovenerol Alp Pannonica Adriat; 2008 Sep; 17(3):133-6. PubMed ID: 18853077
[TBL] [Abstract][Full Text] [Related]
12. Alitretinoin abrogates innate inflammation in palmoplantar pustular psoriasis.
Irla N; Navarini AA; Yawalkar N
Br J Dermatol; 2012 Nov; 167(5):1170-4. PubMed ID: 22612660
[TBL] [Abstract][Full Text] [Related]
13. Successful treatment of generalized pustular psoriasis with the interleukin-1-receptor antagonist Anakinra: lack of correlation with IL1RN mutations.
Viguier M; Guigue P; Pagès C; Smahi A; Bachelez H
Ann Intern Med; 2010 Jul; 153(1):66-7. PubMed ID: 20621920
[No Abstract] [Full Text] [Related]
14. Response to the article by Naik et al entitled "anakinra for refractory pustular psoriasis: A phase II, open label, dose-escalation trial".
Yatsuzuka K; Murakami M
J Am Acad Dermatol; 2023 Mar; 88(3):e145-e146. PubMed ID: 36372378
[No Abstract] [Full Text] [Related]
15. First clinical description of an infant with interleukin-36-receptor antagonist deficiency successfully treated with anakinra.
Rossi-Semerano L; Piram M; Chiaverini C; De Ricaud D; Smahi A; Koné-Paut I
Pediatrics; 2013 Oct; 132(4):e1043-7. PubMed ID: 24019411
[TBL] [Abstract][Full Text] [Related]
16. A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity.
Poulalhon N; Begon E; Lebbé C; Lioté F; Lahfa M; Bengoufa D; Morel P; Dubertret L; Bachelez H
Br J Dermatol; 2007 Feb; 156(2):329-36. PubMed ID: 17223874
[TBL] [Abstract][Full Text] [Related]
17. Two years of experience with etanercept in recalcitrant psoriasis.
Ahmad K; Rogers S
Br J Dermatol; 2007 May; 156(5):1010-4. PubMed ID: 17408393
[TBL] [Abstract][Full Text] [Related]
18. Acrodermatitis continua of Hallopeau treated successfully with ustekinumab and acitretin after failure of tumour necrosis factor blockade and anakinra.
Saunier J; Debarbieux S; Jullien D; Garnier L; Dalle S; Thomas L
Dermatology; 2015; 230(2):97-100. PubMed ID: 25471551
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-17 receptor A blockade with brodalumab in palmoplantar pustular psoriasis: Report on four cases.
Pinter A; Wilsmann-Theis D; Peitsch WK; Mössner R
J Dermatol; 2019 May; 46(5):426-430. PubMed ID: 30786053
[TBL] [Abstract][Full Text] [Related]
20. Complete response of secukinumab in palmoplantar psoriasis.
Rocamora V; Garcías-Ladaria J
Dermatol Online J; 2017 Oct; 23(10):. PubMed ID: 29469799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
